Sisunatovir HCl|CAS Sisunatovir HCl|DC Chemicals

Cas No.:	1903763-83-6
Chemical Name:	1'-((5-(Aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-benzo[d]imidazol-2-yl)methyl)-6'-fluorospiro[cyclopropane-1,3'-indolin]-2'-one hydrochloride
Synonyms:	RV521 hydrochloride; RV-521; RV 521; RV521; Sisunatovir HCl; Sisunatovir hydrochloride;
SMILES:	O=C(C12CC1)N(CC3=NC4=CC(CN)=CC=C4N3CCCC(F)(F)F)C5=C2C=CC(F)=C5.[H]Cl
Formula:	C₂₃H₂₃ClF₄N₄O
M.Wt:	482.91
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Sisunatovir, also known as RV521, is a highly potent fusion inhibitor with efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses. RV521 exhibited a mean IC50 of 1.2 nM against a panel of RSV A and B laboratory strains and clinical isolates with antiviral efficacy in the Balb/C mouse model of RSV infection. Oral bioavailability in preclinical species ranged from 42 to >100% with evidence of highly efficient penetration into lung tissue. In healthy adult human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a significant reduction in viral load and symptoms compared to placebo.

MSDS

TITLE	DOWNLOAD
MSDS_27679_DC51001_1903763-83-6

COA

LOT NO.	DOWNLOAD

Cat. No.	Product name	Field of application
DC51001	Sisunatovir HCl	Sisunatovir, also known as RV521, is a highly potent fusion inhibitor with efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses. RV521 exhibited a mean IC50 of 1.2 nM against a panel of RSV A and B laboratory strains and clinical isolates with antiviral efficacy in the Balb/C mouse model of RSV infection. Oral bioavailability in preclinical species ranged from 42 to >100% with evidence of highly efficient penetration into lung tissue. In healthy adult human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a significant reduction in viral load and symptoms compared to placebo.
DC51000	Sisunatovir (Synonyms: RV521)	Sisunatovir (RV521), an orally available inhibitor of the RSV fusion (RSV-F) protein, exhibits potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses, with IC50s of 1.4 nM and 1.0 nM, respectively.